Expert Review of Pharmacoeconomics & Outcomes Research
Latest Publications

TOTAL DOCUMENTS

1771

(FIVE YEARS 315)

H-INDEX

(FIVE YEARS 5)

Published By Informa Uk (Taylor & Francis)

1744-8379, 1473-7167

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2011216 ◽

2022 ◽

pp. 1-14

Author(s):

Somayeh Afshari ◽

Hosein Ameri ◽

Sajad Baharinya ◽

Morteza Arab-Zozani ◽

Mohammad M Mojahedian

Keyword(s):

Diabetes Mellitus ◽

Systematic Review ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Meta Analysis

Download Full-text

All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2020649 ◽

2021 ◽

Author(s):

Javier Rejas ◽

Antoni Sicras-Mainar ◽

Aram Sicras-Navarro ◽

Nadia Lwoff ◽

Cristina Méndez

Keyword(s):

Real World ◽

Community Acquired Pneumonia

Download Full-text

An update on the economic burden of type 2 diabetes mellitus in China

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2020106 ◽

2021 ◽

Author(s):

Chunchun Ding ◽

Yun Bao ◽

Bona Bai ◽

Xuerun Liu ◽

Bingyin Shi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Economic Burden

Download Full-text

Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2021073 ◽

2021 ◽

Author(s):

Sohail Kamran ◽

Zakir Khan ◽

Muhammad Saqlain ◽

Zahid Nazar ◽

Muska Khan ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Tertiary Care Hospital ◽

Tertiary Care ◽

Antidepressant Drugs ◽

Care Hospital ◽

Major Depressive ◽

Prescription Analysis

Download Full-text

Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2020105 ◽

2021 ◽

Author(s):

Giovanni Tafuri ◽

Andrea Bracco ◽

Jens Grueger

Keyword(s):

European Union ◽

Rare Diseases ◽

The European Union

Download Full-text

Multicriteria decision analysis in health care decision in oncology: a systematic review

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2019580 ◽

2021 ◽

Author(s):

Alessandro Gonçalves Campolina ◽

Erica Aranha Suzumura ◽

Quan Nha Hong ◽

Patrícia Coelho de Soárez

Keyword(s):

Systematic Review ◽

Health Care ◽

Decision Analysis ◽

Multicriteria Decision Analysis ◽

Multicriteria Decision ◽

Health Care Decision ◽

Care Decision

Download Full-text

Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2019017 ◽

2021 ◽

Author(s):

Yaneth Gil-Rojas ◽

Pieralessandro Lasalvia

Keyword(s):

Thrombotic Thrombocytopenic Purpura ◽

Early Treatment ◽

Thrombocytopenic Purpura ◽

Consequence Analysis ◽

Cost Consequence

Download Full-text

Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2017285 ◽

2021 ◽

Author(s):

Xin Yi Wong ◽

Wee Joo Chng ◽

Mohamed Ismail Abdul Aziz ◽

Kwong Ng

Keyword(s):

Multiple Myeloma ◽

Cost Effectiveness ◽

Refractory Multiple Myeloma

Download Full-text

Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2016396 ◽

2021 ◽

Author(s):

Fulton Velez ◽

Danmeng Huang ◽

Lorie Mody ◽

Daniel C. Malone

Keyword(s):

Budget Impact ◽

Opioid Use Disorder ◽

Opioid Use

Download Full-text

Evaluating Discrete Choice Experiment Willingness to Pay [DCE-WTP] analysis, and Relative Social Willingness to Pay [RS-WTP] analysis in a Health Technology Assessment of a treatment for an ultra-rare childhood disease [CLN2]

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.2014324 ◽

2021 ◽

Author(s):

Domenico Moro ◽

Michael Schlander ◽

Harry Telser ◽

Oriol Sola-Morales ◽

Michael David Clark ◽

...

Keyword(s):

Willingness To Pay ◽

Health Technology Assessment ◽

Discrete Choice Experiment ◽

Discrete Choice ◽

Technology Assessment ◽

Choice Experiment ◽

Health Technology ◽

Childhood Disease

Download Full-text

Expert Review of Pharmacoeconomics & Outcomes ResearchLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Informa Uk (Taylor & Francis)

Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain

An update on the economic burden of type 2 diabetes mellitus in China

Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach

Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective

Multicriteria decision analysis in health care decision in oncology: a systematic review

Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia

Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder

Evaluating Discrete Choice Experiment Willingness to Pay [DCE-WTP] analysis, and Relative Social Willingness to Pay [RS-WTP] analysis in a Health Technology Assessment of a treatment for an ultra-rare childhood disease [CLN2]

Expert Review of Pharmacoeconomics & Outcomes Research
Latest Publications